

HM2023-07: Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

1. diagnosed with multiple myeloma that has not responded to treatment or has reoccurred after at least one treatment 2. able to care for self with some assistance

Exclusion Criteria:

1. active cancer in central nervous system or clinical symptoms 2. maximum amount of steroids taken in the past two weeks (study staff will review) 3. disease hasn't responded to this type of drug (anti-CD38 monoclonal antibody)

Conditions & Interventions

Conditions:

Cancer

Keywords:

Multiple Myeloma

More Information

Description: Talquetamab is an experimental medication being studied to see if it may be beneficial in the treatment of multiple myeloma.

Study Contact: Daniel O'Leary - dholeary@umn.edu

Principal Investigator: Daniel O'Leary

IRB

Number: STUDY00018679

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.